1 June 2024 true No description of principal activity Taxfiler 2024.6 true 11338827 business:PrivateLimitedCompanyLtd 2024-06-01 2025-05-31 11338827 2024-05-31 11338827 business:EntityNoLongerTradingButTradedInPast 2024-06-01 2025-05-31 11338827 2024-06-01 2025-05-31 11338827 business:AuditExempt-NoAccountantsReport 2024-06-01 2025-05-31 11338827 business:FilletedAccounts 2024-06-01 2025-05-31 11338827 2025-05-31 11338827 business:Director1 2024-06-01 2025-05-31 11338827 business:RegisteredOffice 2024-06-01 2025-05-31 11338827 2024-05-31 11338827 core:WithinOneYear 2025-05-31 11338827 core:WithinOneYear 2024-05-31 11338827 core:ShareCapital core:PreviouslyStatedAmount 2025-05-31 11338827 core:ShareCapital core:PreviouslyStatedAmount 2024-05-31 11338827 core:RetainedEarningsAccumulatedLosses core:PreviouslyStatedAmount 2025-05-31 11338827 core:RetainedEarningsAccumulatedLosses core:PreviouslyStatedAmount 2024-05-31 11338827 core:PreviouslyStatedAmount 2025-05-31 11338827 core:PreviouslyStatedAmount 2024-05-31 11338827 business:SmallEntities 2024-06-01 2025-05-31 11338827 countries:EnglandWales 2024-06-01 2025-05-31 11338827 core:MotorVehicles 2024-06-01 2025-05-31 11338827 core:MotorVehicles 2024-05-31 11338827 core:ComputerEquipment 2024-05-31 11338827 core:MotorVehicles 2025-05-31 11338827 core:ComputerEquipment 2025-05-31 11338827 2023-06-01 2024-05-31 iso4217:GBP xbrli:pure
Company Registration No. 11338827 (England and Wales)
Pharm.Garib Ltd Unaudited accounts for the year ended 31 May 2025
Pharm.Garib Ltd Unaudited accounts Contents
Page
Company information
3
Statement of financial position
4
Notes to the accounts
5
- 2 -
Pharm.Garib Ltd Company Information for the year ended 31 May 2025
Director
Kazan Garib
Company Number
11338827 (England and Wales)
Registered Office
111 TELFORD WAY HAYES UB4 9TH ENGLAND
Accountants
Enso Accountants Ltd 189c Mauldeth Road Manchester M191BA
- 3 -
Pharm.Garib Ltd Statement of financial position as at 31 May 2025
2025
2024
Notes
£
£
Fixed assets
Tangible assets
4
7,306
7,306
Current assets
Debtors
5
(3,673)
(3,673)
Cash at bank and in hand
5,526
5,526
1,853
1,853
Creditors: amounts falling due within one year
6
(1,667)
(1,667)
Net current assets
186
186
Net assets
7,492
7,492
Capital and reserves
Called up share capital
100
100
Profit and loss account
7,392
7,392
Shareholders' funds
7,492
7,492
For the year ending 31 May 2025 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 13 February 2026 and were signed on its behalf by
Kazan Garib Director Company Registration No. 11338827
- 4 -
Pharm.Garib Ltd Notes to the Accounts for the year ended 31 May 2025
1
Statutory information
Pharm.Garib Ltd is a private company, limited by shares, registered in England and Wales, registration number 11338827. The registered office is 111 TELFORD WAY, HAYES, UB4 9TH, ENGLAND.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Motor vehicles
20% Reducing Balance
Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Turnover from the sale of goods is recognised when goods have been delivered to customers such that risks and rewards of ownership have transferred to them. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Going concern
The financial statements have been prepared on a going concern basis, which assumes that the company will continue in operational existence for the foreseeable future. The directors have carefully reviewed the company's current financial position, future cash flows, and the availability of financing, and they have assessed the company's ability to meet its obligations as they fall due.
- 5 -
Pharm.Garib Ltd Notes to the Accounts for the year ended 31 May 2025
4
Tangible fixed assets
Motor vehicles
Computer equipment
Total
£
£
£
Cost or valuation
At cost
At cost
At 1 June 2024
15,478
1,100
16,578
At 31 May 2025
15,478
1,100
16,578
Depreciation
At 1 June 2024
9,272
-
9,272
At 31 May 2025
9,272
-
9,272
Net book value
At 31 May 2025
6,206
1,100
7,306
At 31 May 2024
6,206
1,100
7,306
5
Debtors
2025
2024
£
£
Amounts falling due within one year
Other debtors
(3,673)
(3,673)
6
Creditors: amounts falling due within one year
2025
2024
£
£
Taxes and social security
1,667
1,667
7
Average number of employees
During the year the average number of employees was 1 (2024: 1).
- 6 -